Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Mallinckrodt
Dow
McKesson
Express Scripts

Last Updated: May 25, 2022

VABOMERE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Vabomere patents expire, and what generic alternatives are available?

Vabomere is a drug marketed by Rempex and is included in one NDA. There are six patents protecting this drug.

This drug has fifty-two patent family members in twenty-six countries.

The generic ingredient in VABOMERE is meropenem; vaborbactam. There are thirty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the meropenem; vaborbactam profile page.

DrugPatentWatch® Generic Entry Outlook for Vabomere

Vabomere was eligible for patent challenges on August 29, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 29, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for VABOMERE
Drug Prices for VABOMERE

See drug prices for VABOMERE

DrugPatentWatch® Estimated Generic Entry Opportunity Date for VABOMERE
Generic Entry Date for VABOMERE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VABOMERE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Biomedical Advanced Research and Development AuthorityPhase 1
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)Phase 1
Department of Health and Human ServicesPhase 1

See all VABOMERE clinical trials

US Patents and Regulatory Information for VABOMERE

VABOMERE is protected by six US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VABOMERE is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VABOMERE

Pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX

Cyclic boronic acid ester derivatives and therapeutic uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX

Cyclic boronic acid ester derivatives and therapeutic uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED

Cyclic boronic acid ester derivatives and therapeutic uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Cyclic boronic acid ester derivatives and therapeutic uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS

FDA Regulatory Exclusivity protecting VABOMERE

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rempex VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Rempex VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Rempex VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Rempex VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Rempex VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VABOMERE

When does loss-of-exclusivity occur for VABOMERE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 11289615
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2013003045
Estimated Expiration: See Plans and Pricing

Canada

Patent: 07546
Estimated Expiration: See Plans and Pricing

Chile

Patent: 13000399
Estimated Expiration: See Plans and Pricing

China

Patent: 3180328
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 80667
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0200741
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 03514
Estimated Expiration: See Plans and Pricing

Patent: 12676
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 03514
Estimated Expiration: See Plans and Pricing

Patent: 12676
Estimated Expiration: See Plans and Pricing

Patent: 66778
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 40086
Estimated Expiration: See Plans and Pricing

Patent: 48859
Estimated Expiration: See Plans and Pricing

Patent: 900017
Estimated Expiration: See Plans and Pricing

Patent: 900018
Estimated Expiration: See Plans and Pricing

Israel

Patent: 4564
Estimated Expiration: See Plans and Pricing

Japan

Patent: 66978
Estimated Expiration: See Plans and Pricing

Patent: 02742
Estimated Expiration: See Plans and Pricing

Patent: 54861
Estimated Expiration: See Plans and Pricing

Patent: 13535502
Estimated Expiration: See Plans and Pricing

Patent: 17052794
Estimated Expiration: See Plans and Pricing

Patent: 20002178
Estimated Expiration: See Plans and Pricing

Patent: 21073212
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 2020519
Estimated Expiration: See Plans and Pricing

Patent: 2020521
Estimated Expiration: See Plans and Pricing

Patent: 12676
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 8653
Estimated Expiration: See Plans and Pricing

Patent: 13001517
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 7354
Estimated Expiration: See Plans and Pricing

Norway

Patent: 19013
Estimated Expiration: See Plans and Pricing

Patent: 19014
Estimated Expiration: See Plans and Pricing

Poland

Patent: 03514
Estimated Expiration: See Plans and Pricing

Patent: 12676
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 03514
Estimated Expiration: See Plans and Pricing

Patent: 12676
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 99791
Estimated Expiration: See Plans and Pricing

Patent: 13104951
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 310
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 7757
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 12676
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1987091
Estimated Expiration: See Plans and Pricing

Patent: 2087313
Estimated Expiration: See Plans and Pricing

Patent: 2205755
Estimated Expiration: See Plans and Pricing

Patent: 130099923
Estimated Expiration: See Plans and Pricing

Patent: 190066084
Estimated Expiration: See Plans and Pricing

Patent: 200028043
Estimated Expiration: See Plans and Pricing

Spain

Patent: 91468
Estimated Expiration: See Plans and Pricing

Patent: 89177
Estimated Expiration: See Plans and Pricing

Turkey

Patent: 1815323
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VABOMERE around the world.

Country Patent Number Title Estimated Expiration
Canada 2807546 DERIVES CYCLIQUES D'ESTERS D'ACIDE BORONIQUE ET LEURS UTILISATIONS THERAPEUTIQUES (CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF) See Plans and Pricing
Japan 2020002178 環状ボロン酸エステル誘導体およびその治療的使用 (CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF) See Plans and Pricing
South Korea 20190066084 고리형 보론산 에스터 유도체의 제조방법 (METHOD FOR PREPARING CYCLIC BORONIC ACID ESTER DERIVATIVES) See Plans and Pricing
Mexico 348653 DERIVADOS ESTER DE ACIDO BORONICO CICLICO Y SUS USOS TERAPEUTICOS. (CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF.) See Plans and Pricing
Japan 2017052794 環状ボロン酸エステル誘導体およびその治療的使用 (CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VABOMERE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2603514 19C1022 France See Plans and Pricing PRODUCT NAME: VABORBACTAM, ET/OU UN SEL ET/OU UN HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/18/1334 20181122
2603514 CA 2019 00016 Denmark See Plans and Pricing PRODUCT NAME: VABORBACTAM, OG/ELLER ET SALT OG/ELLER HYDRAT HERAF; REG. NO/DATE: EU/1/18/1334 20181122
2603514 1990019-0 Sweden See Plans and Pricing PRODUCT NAME: VABORBACTAM, AND /OR A SALT AND/OR HYDRATE THEREOF; REG. NO/DATE: EU/1/18/1334 20181122
2603514 122019000027 Germany See Plans and Pricing PRODUCT NAME: KOMBINATION VON VABORBACTAM, ODER EIN SALZ ODER EIN HYDRAT DAVON, UND MEROPENEM, ODER EIN SALZ ODER EIN HYDRAT DAVON, INSBESONDERE MEROPENEMTRIHYDRAT; REGISTRATION NO/DATE: EU/1/18/1334 20181120
2603514 19C1021 France See Plans and Pricing PRODUCT NAME: COMBINAISON DE VABORBACTAME, ET/OU D'UN SEL ET/OU D'UN HYDRATE DE CELUI-CI, ET DE MEROPENEME, ET/OU D'UN SEL ET/OU D'UN HYDRATE DE CELUI-CI, EN PARTICULIER DE MEROPENEME TRIHYDRATE; REGISTRATION NO/DATE: EU/1/18/1334 20181122
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Merck
Medtronic
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.